RA Capital Management’s Editas Medicine EDIT Stock Holding History

RA Capital Management’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$28.8M	Buy	+8,889,000	New	+$26M	0.25%	54

Other funds holding EDIT

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

GordonMD Global Investments Beverely Hills, California $207M AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

RA Capital Management's EDIT Position: Q2 2026 in Review

RA Capital Management opened a new position in Editas Medicine (EDIT) in Q2 2026: 8,889,000 shares worth $28.8M. The stake represents 0.25% of the portfolio and ranks #54 among its holdings.

198 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

RA Capital Management held 8,889,000 shares of Editas Medicine worth $28.8M as of Q2 2026.
Editas Medicine was a new RA Capital Management position in Q2 2026.
Editas Medicine made up 0.25% of RA Capital Management's portfolio in Q2 2026, its #54 holding.
198 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on RA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.